A
Alethia BioTherapeutics
Immunotherapeutics against disease-specific targets
About Alethia BioTherapeutics
Alethia Biotherapeutics is a biotechnology company focused on developing novel therapies for the treatment of invasive carcinomas. The company's core product, AB 16B5, is a humanized IgG2 antibody that targets and inhibits the epithelial to mesenchymal transition (EMT), a process that allows cancer cells to become more invasive and resistant to chemotherapy. By blocking EMT, AB 16B5 has shown in preclinical studies to increase the effectiveness of standard chemotherapy and reduce cancer cell invasion.
Alethia primarily serves the oncology market, targeting patients with advanced carcinomas who require more effective treatment options. The company operates within the biopharmaceutical industry, leveraging cutting-edge research and development to bring innovative cancer therapies to market.
Alethia's business model involves advancing its drug candidates through clinical trials, securing regulatory approvals, and ultimately partnering with larger pharmaceutical companies for commercialization. Revenue is generated through licensing agreements, milestone payments, and royalties on product sales.
Source: Dealroom company dataNews
Open roles
Alethia BioTherapeutics in the Montreal ecosystem
The Alethia BioTherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
GO Capital Fund
Business Development Bank of Canada
GeneChem
Epicentre Technologies
BDC Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alethia BioTherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alethia BioTherapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

